Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
24 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Zyngenia, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Zyngenia, Inc. - Product Pipeline Review - 2014', provides an overview of the Zyngenia, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Zyngenia, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Zyngenia, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Zyngenia, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Zyngenia, Inc.'s pipeline products Reasons to buy - Evaluate Zyngenia, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Zyngenia, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Zyngenia, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Zyngenia, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zyngenia, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Zyngenia, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Zyngenia, Inc. Snapshot 4 Zyngenia, Inc. Overview 4 Key Information 4 Key Facts 4 Zyngenia, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Zyngenia, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Partnered Products 9 Partnered Products/Combination Treatment Modalities 10 Zyngenia, Inc. - Pipeline Products Glance 11 Zyngenia, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Zyngenia, Inc. - Drug Profiles 13 Monoclonal Antibody for Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Monoclonal Antibody for Multiple Myleoma 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Monoclonal Antibody to Antagonize HER-1 and HER-3 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Monoclonal Antibody to Inhibit Ang-2 and TNF-a 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibody to Antagonize HER-2 for Metastatic Breast Cancer 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Zyngenia, Inc. - Pipeline Analysis 18 Zyngenia, Inc. - Pipeline Products by Target 18 Zyngenia, Inc. - Pipeline Products by Molecule Type 19 Zyngenia, Inc. - Pipeline Products by Mechanism of Action 20 Zyngenia, Inc. - Recent Pipeline Updates 21 Zyngenia, Inc. - Locations And Subsidiaries 22 Head Office 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables Zyngenia, Inc., Key Information 4 Zyngenia, Inc., Key Facts 4 Zyngenia, Inc. - Pipeline by Indication, 2014 6 Zyngenia, Inc. - Pipeline by Stage of Development, 2014 7 Zyngenia, Inc. - Monotherapy Products in Pipeline, 2014 8 Zyngenia, Inc. - Partnered Products in Pipeline, 2014 9 Zyngenia, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10 Zyngenia, Inc. - Preclinical, 2014 11 Zyngenia, Inc. - Discovery, 2014 12 Zyngenia, Inc. - Pipeline by Target, 2014 18 Zyngenia, Inc. - Pipeline by Molecule Type, 2014 19 Zyngenia, Inc. - Pipeline Products by Mechanism of Action, 2014 20 Zyngenia, Inc. - Recent Pipeline Updates, 2014 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.